{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:48:09Z","timestamp":1786981689804,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-024-04110-9","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T07:02:06Z","timestamp":1718002926000},"page":"3285-3293","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Is denosumab an efficient and safe drug for osteoporosis in dialysis patients? Considerations and state of the art about its use in this setting"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0664-4600","authenticated-orcid":false,"given":"Marco","family":"Simonini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Bologna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4481-5693","authenticated-orcid":false,"given":"Giuseppe","family":"Vezzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"key":"4110_CR1","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/ki.2013.547","volume":"86","author":"KL Naylor","year":"2014","unstructured":"Naylor KL, McArthur E, Leslie WD, Fraser LA, Jamal SA, Cadarette SM et al (2014) The three-year incidence of fracture in chronic kidney disease. Kidney Int 86:810\u2013818. https:\/\/doi.org\/10.1038\/ki.2013.547","journal-title":"Kidney Int"},{"key":"4110_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00774-012-0411-z","volume":"31","author":"M Wakasugi","year":"2013","unstructured":"Wakasugi M, Kazama JJ, Taniguchi M, Wada A, Iseki K, Tsubakihara Y et al (2013) Increased risk of hip fracture among Japanese hemodialysis patients. J Bone Min Metab 31:315\u2013321. https:\/\/doi.org\/10.1007\/s00774-012-0411-z","journal-title":"J Bone Min Metab"},{"key":"4110_CR3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1053\/j.ajkd.2020.02.450","volume":"76","author":"T Vilaca","year":"2020","unstructured":"Vilaca T, Salam S, Schini M, Harnan S, Sutton A, Poku E et al (2020) Risks of hip and nonvertebral fractures in patients with CKD G3a\u2013G5D: A systematic review and meta-analysis. Am J Kidney Dis 76:521\u2013532. https:\/\/doi.org\/10.1053\/j.ajkd.2020.02.450","journal-title":"Am J Kidney Dis"},{"key":"4110_CR4","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1053\/j.ajkd.2013.02.368","volume":"62","author":"TJ Arneson","year":"2013","unstructured":"Arneson TJ, Li S, Liu J, Kilpatrick RD, Newsome BB, St. Peter WL, (2013) Trends in hip fracture rates in US hemodialysis patients, 1993\u20132010. Am J Kidney Dis 62:747\u2013754. https:\/\/doi.org\/10.1053\/j.ajkd.2013.02.368","journal-title":"Am J Kidney Dis"},{"key":"4110_CR5","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1093\/ndt\/gfw073","volume":"31","author":"D Hansen","year":"2016","unstructured":"Hansen D, Olesen JB, Gislason GH, Abrahamsen B, Hommel K (2016) Risk of fracture in adults on renal replacement therapy: a Danish national cohort study. Nephrol Dial Transplant 31:1654\u20131662. https:\/\/doi.org\/10.1093\/ndt\/gfw073","journal-title":"Nephrol Dial Transplant"},{"key":"4110_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.bone.2013.07.002","volume":"56","author":"H Tanaka","year":"2013","unstructured":"Tanaka H, Iwasaki Y, Yamato H, Mori Y, Komaba H, Watanabe H et al (2013) p-Cresyl sulfate induces osteoblast dysfunction through activating JNK and p38 MAPK pathways. Bone 56:347\u2013354. https:\/\/doi.org\/10.1016\/j.bone.2013.07.002","journal-title":"Bone"},{"key":"4110_CR7","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/sj.ki.5002097","volume":"71","author":"T Nii-Kono","year":"2007","unstructured":"Nii-Kono T, Iwasaki Y, Uchida M, Fujieda A, Hosokawa A, Motojima M et al (2007) Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int 71:738\u2013743. https:\/\/doi.org\/10.1038\/sj.ki.5002097","journal-title":"Kidney Int"},{"key":"4110_CR8","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/2211-5463.12258","volume":"7","author":"K Watanabe","year":"2017","unstructured":"Watanabe K, Tominari T, Hirata M, Matsumoto C, Hirata J, Murphy G et al (2017) Indoxyl sulfate, a uremic toxin in chronic kidney disease, suppresses both bone formation and bone resorption. FEBS Open Bio 7:1178\u20131185. https:\/\/doi.org\/10.1002\/2211-5463.12258","journal-title":"FEBS Open Bio"},{"key":"4110_CR9","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.bone.2013.07.037","volume":"57","author":"Y Iwasaki","year":"2013","unstructured":"Iwasaki Y, Kazama JJ, Yamato H, Fukagawa M (2013) Accumulated uremic toxins attenuate bone mechanical properties in rats with chronic kidney disease. Bone 57:477\u2013483. https:\/\/doi.org\/10.1016\/j.bone.2013.07.037","journal-title":"Bone"},{"key":"4110_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.kint.2015.12.004","volume":"89","author":"T Drueke","year":"2016","unstructured":"Drueke T, Massy ZA (2016) Changing bone patterns with progression of chronic kidney disease. Kidney Int 89:289\u2013302. https:\/\/doi.org\/10.1016\/j.kint.2015.12.004","journal-title":"Kidney Int"},{"key":"4110_CR11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/ki.1994.380","volume":"46","author":"WG Goodman","year":"1994","unstructured":"Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre G et al (1994) Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46:160\u2013166. https:\/\/doi.org\/10.1038\/ki.1994.380","journal-title":"Kidney Int"},{"key":"4110_CR12","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/kisup.2013.93","volume":"3","author":"JJ Kazama","year":"2013","unstructured":"Kazama JJ, Iwasaki Y, Fukagawa M (2013) Uremic osteoporosis. Kidney Int Suppl 3:446\u2013450. https:\/\/doi.org\/10.1038\/kisup.2013.93","journal-title":"Kidney Int Suppl"},{"key":"4110_CR13","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1053\/j.ajkd.2020.12.024","volume":"78","author":"M Pazianas","year":"2021","unstructured":"Pazianas M, Miller PD (2021) Osteoporosis and chronic kidney disease\u2013mineral and bone disorder (CKD-MBD): back to basics. Am J Kidney Dis 78:582\u2013589. https:\/\/doi.org\/10.1053\/j.ajkd.2020.12.024","journal-title":"Am J Kidney Dis"},{"key":"4110_CR14","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1681\/ASN.2009121208","volume":"21","author":"TL Nickolas","year":"2010","unstructured":"Nickolas TL, Stein E, Cohen A, Thomas V, Staron RB, McMahon DJ et al (2010) Bone mass and microarchitecture in CKD patients with fracture. J Am Soc Nephrol 21:1371\u20131380. https:\/\/doi.org\/10.1681\/ASN.2009121208","journal-title":"J Am Soc Nephrol"},{"key":"4110_CR15","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1002\/jbmr.1916","volume":"28","author":"TL Nickolas","year":"2013","unstructured":"Nickolas TL, Stein E, Dworakowski E, Nishiyama KK, Mafo Komandah-Kosseh M, Zhang CA et al (2013) Rapid cortical bone loss in patients with chronic kidney disease. J Bone Min Res 28:1811\u20131820. https:\/\/doi.org\/10.1002\/jbmr.1916","journal-title":"J Bone Min Res"},{"key":"4110_CR16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/ki.2009.188","volume":"113","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 113:S1\u2013S130. https:\/\/doi.org\/10.1038\/ki.2009.188","journal-title":"Kidney Int Suppl"},{"key":"4110_CR17","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1053\/j.ajkd.2015.06.023","volume":"67","author":"SM Sprague","year":"2016","unstructured":"Sprague SM, Bellorin-Font E, Jorgetti V, Carvalho AB, Malluche HH, Ferreira A et al (2016) Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis 67:559\u2013566. https:\/\/doi.org\/10.1053\/j.ajkd.2015.06.023","journal-title":"Am J Kidney Dis"},{"key":"4110_CR18","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1002\/jbmr.4440","volume":"36","author":"M Fusaro","year":"2021","unstructured":"Fusaro M, Cianciolo G, Tripepi G, Plebani M, Aghi A, Politi C et al (2021) Oral calcitriol use, vertebral fractures, and vitamin K in hemodialysis patients: A cross-sectional study. J Bone Min Res 36:2361\u20132370. https:\/\/doi.org\/10.1002\/jbmr.4440","journal-title":"J Bone Min Res"},{"key":"4110_CR19","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u2013420. https:\/\/doi.org\/10.1056\/NEJMoa1305224","journal-title":"N Engl J Med"},{"key":"4110_CR20","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1210\/jc.2017-02163","volume":"103","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meiser PD, Miller PD et al (2018) A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab 103:3183\u20133193. https:\/\/doi.org\/10.1210\/jc.2017-02163","journal-title":"J Clin Endocrinol Metab"},{"key":"4110_CR21","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1002\/jbmr.149","volume":"25","author":"IR Reid","year":"2010","unstructured":"Reid IR, Miller PD, Brown JP, Kendler DL, Fahrleitner-Pammer A, Valter I et al (2010) Effects of denosumab on bone histomorphometry: The FREEDOM and STAND Studies. J Bone Min Research 25:2256\u20132265. https:\/\/doi.org\/10.1002\/jbmr.149","journal-title":"J Bone Min Research"},{"key":"4110_CR22","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1002\/jbmr.2236","volume":"29","author":"JP Brown","year":"2014","unstructured":"Brown JP, Reid IR, Wagman RB, Kendler D, Miller PD, Beck Jensen JE et al (2014) Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extension. J Bone Min Research 29:2051\u20132056. https:\/\/doi.org\/10.1002\/jbmr.2236","journal-title":"J Bone Min Research"},{"key":"4110_CR23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513\u2013523. https:\/\/doi.org\/10.1016\/S2213-8587(17)30138-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4110_CR24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/jbm4.10117","volume":"2","author":"MJ Damasiewicz","year":"2018","unstructured":"Damasiewicz MJ, Nickolas TL (2018) Rethinking bone disease in kidney disease. JBMR Plus 2:309\u2013322. https:\/\/doi.org\/10.1002\/jbm4.10117","journal-title":"JBMR Plus"},{"key":"4110_CR25","doi-asserted-by":"publisher","first-page":"962","DOI":"10.2215\/CJN.11031017","volume":"13","author":"P Khairallah","year":"2018","unstructured":"Khairallah P, Nickolas TL (2018) Management of osteoporosis in CKD. Clin J Am Soc Nephrol 13:962\u2013969. https:\/\/doi.org\/10.2215\/CJN.11031017","journal-title":"Clin J Am Soc Nephrol"},{"key":"4110_CR26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1053\/j.ajkd.2021.06.031","volume":"79","author":"C Ginsberg","year":"2022","unstructured":"Ginsberg C, Ix JH (2022) Diagnosis and management of osteoporosis in advanced kidney disease: a review. Am J Kidney Dis 79:427\u2013436. https:\/\/doi.org\/10.1053\/j.ajkd.2021.06.031","journal-title":"Am J Kidney Dis"},{"key":"4110_CR27","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765. https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"key":"4110_CR28","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/jbmr.403","volume":"26","author":"SA Jamal","year":"2011","unstructured":"Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S et al (2011) Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26:1829\u20131835. https:\/\/doi.org\/10.1002\/jbmr.403","journal-title":"J Bone Miner Res"},{"key":"4110_CR29","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1210\/clinem\/dgaa851","volume":"106","author":"A Broadwell","year":"2021","unstructured":"Broadwell A, Chines A, Ebeling PR, Franek E, Huang S, Smith S et al (2021) Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease. J Clin Endocrinol Metab 106:397\u2013409. https:\/\/doi.org\/10.1210\/clinem\/dgaa851","journal-title":"J Clin Endocrinol Metab"},{"key":"4110_CR30","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/jbmr.1613","volume":"27","author":"GA Block","year":"2012","unstructured":"Block GA, Bone HG, Fang L, Lee E, Padhi D (2012) A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27:1471\u20131479. https:\/\/doi.org\/10.1002\/jbmr.1613","journal-title":"J Bone Miner Res"},{"key":"4110_CR31","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1210\/jc.2014-1154","volume":"99","author":"CL Chen","year":"2014","unstructured":"Chen CL, Chen NC, Hsu CY, Chou KJ, Lee PT, Fang HC et al (2014) An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis. J Clin Endocrinol Metab 99:2426\u20132432. https:\/\/doi.org\/10.1210\/jc.2014-1154","journal-title":"J Clin Endocrinol Metab"},{"key":"4110_CR32","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1210\/jc.2015-1259","volume":"100","author":"CL Chen","year":"2015","unstructured":"Chen CL, Chen NC, Liang HL, Hsu CY, Chou KJ, Fang HC et al (2015) Effects of denosumab and calcitriol on severe secondary hyperparathyroidism in dialysis patients with low bone mass. J Clin Endocrinol Metab 100:2784\u20132792. https:\/\/doi.org\/10.1210\/jc.2015-1259","journal-title":"J Clin Endocrinol Metab"},{"key":"4110_CR33","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s00198-020-05391-3","volume":"31","author":"CL Chen","year":"2020","unstructured":"Chen CL, Chen NC, Wu FZ, Wu MT (2020) Impact of denosumab on cardiovascular calcification in patients with secondary hyperparathyroidism undergoing dialysis: a pilot study. Osteoporos Int 31:1507\u20131516. https:\/\/doi.org\/10.1007\/s00198-020-05391-3","journal-title":"Osteoporos Int"},{"key":"4110_CR34","doi-asserted-by":"publisher","first-page":"6218129","DOI":"10.1155\/2017\/6218129","volume":"2017","author":"H Takami","year":"2017","unstructured":"Takami H, Washio K, Gotoh H (2017) Denosumab for male hemodialysis patients with low bone mineral density: a case-control study. Int J Nephrol 2017:6218129. https:\/\/doi.org\/10.1155\/2017\/6218129","journal-title":"Int J Nephrol"},{"key":"4110_CR35","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/jbmr.3676","volume":"34","author":"K Iseri","year":"2019","unstructured":"Iseri K, Watanabe M, Yoshikawa H, Mitsui H, Endo T, Yamamoto Y et al (2019) Effects of denosumab and alendronate on bone health and vascular function in hemodialysis patients: a randomized, controlled trial. J Bone Miner Res 34:1014\u20131024. https:\/\/doi.org\/10.1002\/jbmr.3676","journal-title":"J Bone Miner Res"},{"key":"4110_CR36","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1038\/s41598-020-59143-8","volume":"10","author":"K Kunizawa","year":"2020","unstructured":"Kunizawa K, Hiramatsu R, Hoshino J, Mizuno H, Ozawa Y, Sekine A et al (2020) Denosumab for dialysis patients with osteoporosis: a cohort study. Sci Rep 10:2496. https:\/\/doi.org\/10.1038\/s41598-020-59143-8","journal-title":"Sci Rep"},{"key":"4110_CR37","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/ndt\/gfaa359","volume":"36","author":"R Hiramatsu","year":"2021","unstructured":"Hiramatsu R, Ubara Y, Sawa N, Sakai A (2021) Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: a 2-year observational study. Nephrol Dial Transplant 36:1900\u20131907. https:\/\/doi.org\/10.1093\/ndt\/gfaa359","journal-title":"Nephrol Dial Transplant"},{"key":"4110_CR38","doi-asserted-by":"publisher","first-page":"7781","DOI":"10.1038\/s41598-022-12029-3","volume":"12","author":"M Hori","year":"2022","unstructured":"Hori M, Yasuda K, Takahashi H, Kondo C, Shirasawa Y, Ishimaru Y et al (2022) Effects of bone turnover status on the efficacy and safety of denosumab among haemodialysis patients. Sci Rep 12:7781. https:\/\/doi.org\/10.1038\/s41598-022-12029-3","journal-title":"Sci Rep"},{"key":"4110_CR39","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40620-016-0334-1","volume":"30","author":"F Festuccia","year":"2017","unstructured":"Festuccia F, Jafari MT, Moioli A, Fofi C, Barberi S, Amendola S et al (2017) Safety and efficacy of denosumab in osteoporotic hemodialysed patients. J Nephrol 30:271\u2013279. https:\/\/doi.org\/10.1007\/s40620-016-0334-1","journal-title":"J Nephrol"},{"key":"4110_CR40","doi-asserted-by":"publisher","first-page":"70","DOI":"10.5414\/CN110473","volume":"97","author":"SH Han","year":"2022","unstructured":"Han SH, Jo HA, Han KH, Han SY (2022) Lower response to denosumab in diabetes patients on hemodialysis. Clin Nephrol 97:70\u201377. https:\/\/doi.org\/10.5414\/CN110473","journal-title":"Clin Nephrol"},{"key":"4110_CR41","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.3390\/jcm13051462","volume":"13","author":"H Kim","year":"2024","unstructured":"Kim H, Lee EJ, Woo S, Rho S, Jung JY (2024) Effect of denosumab on bone health, vascular calcification, and health-related quality of life in hemodialysis patients with osteoporosis: a prospective observational study. J Clin Med 13:1462. https:\/\/doi.org\/10.3390\/jcm13051462","journal-title":"J Clin Med"},{"key":"4110_CR42","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2215\/CJN.0000000000000213","volume":"18","author":"K Iseri","year":"2023","unstructured":"Iseri K, Mizobuchi M, Winzenrieth R, Humbert L, Saitou T, Kato T et al (2023) Long-term effect of denosumab on bone disease in patients with CKD. Clin J Am Soc Nephrol 18:1195\u20131203. https:\/\/doi.org\/10.2215\/CJN.0000000000000213","journal-title":"Clin J Am Soc Nephrol"},{"key":"4110_CR43","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/kisup.2013.94","volume":"3","author":"K Yokoyama","year":"2013","unstructured":"Yokoyama K, Taniguchi M, Fukagawa M (2013) A japanese approach for CKD-MBD. Kidney Int Suppl 3:451\u2013456. https:\/\/doi.org\/10.1038\/kisup.2013.94","journal-title":"Kidney Int Suppl"},{"key":"4110_CR44","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/ndt\/gfaa192","volume":"36","author":"P Evenepoel","year":"2021","unstructured":"Evenepoel P, Cunningham J, Ferrari S, Haarhaus M, Javaid MK, Lafage-Proust MH et al (2021) European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4\u2013G5D. Nephrol Dial Transplant 36:42\u201359. https:\/\/doi.org\/10.1093\/ndt\/gfaa192","journal-title":"Nephrol Dial Transplant"},{"key":"4110_CR45","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/jbmr.2480","volume":"30","author":"MS Ominsky","year":"2015","unstructured":"Ominsky MS, Libanati C, Niu QT, Boyce RW, Kostenuik PJ, Wagman RB et al (2015) Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab. J Bone Miner Res 30:1280\u20131289. https:\/\/doi.org\/10.1002\/jbmr.2480","journal-title":"J Bone Miner Res"},{"key":"4110_CR46","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","volume":"26","author":"S Papapoulos","year":"2015","unstructured":"Papapoulos S, Lippuner K, Roux LCJF, Kendler DL, Lewiecki EM et al (2015) The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension study. Osteoporos Int 26:2773\u20132783. https:\/\/doi.org\/10.1007\/s00198-015-3234-7","journal-title":"Osteoporos Int"},{"key":"4110_CR47","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R, Gilchrist N, Beck Jensen JE, McClung M et al (2018) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-Controlled FREEDOM trial and its extension. J Bone Miner Res 33:190\u2013198. https:\/\/doi.org\/10.1002\/jbmr.3337","journal-title":"J Bone Miner Res"},{"key":"4110_CR48","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1001\/jama.2023.28239","volume":"331","author":"ST Bird","year":"2024","unstructured":"Bird ST, Smith ER, Gelperin K, Jung TH, Thompson A, Kambhampati R et al (2024) Severe hypocalcemia with denosumab among older female dialysis-dependent patients. JAMA 331:491\u2013499 https:\/\/doi.org\/10.1001\/jama.2023.28239","journal-title":"JAMA"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-04110-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-024-04110-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-04110-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T12:30:51Z","timestamp":1726489851000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-024-04110-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,10]]},"references-count":48,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["4110"],"URL":"https:\/\/doi.org\/10.1007\/s11255-024-04110-9","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,10]]},"assertion":[{"value":"9 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}